Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intra-Cellular Therapies Inc. - Common Stock (NQ:ITCI)

131.88 +0.07 (+0.05%)
Streaming Delayed Price Updated: 1:24 PM EDT, Mar 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,226,256
Open 131.84
Bid (Size) 131.88 (4)
Ask (Size) 131.89 (30)
Prev. Close 131.81
Today's Range 131.80 - 131.94
52wk Range 64.09 - 131.87
Shares Outstanding 94,324,313
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Evaluating INTRA-CELLULAR THERAPIES INC (NASDAQ:ITCI) using Mark Minervini’s winning stock formula
A fundamental and technical analysis of (NASDAQ:ITCI): Should you consider INTRA-CELLULAR THERAPIES INC (NASDAQ:ITCI) for high growth investing? 
Via Chartmill
Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy'
Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion 
Via Benzinga

Performance

YTD
+56.6%
+56.6%
1 Month
+2.9%
+2.9%
3 Month
+58.0%
+58.0%
6 Month
+80.2%
+80.2%
1 Year
+93.2%
+93.2%

More News

Read More
INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI
From Kahn Swick & Foti, LLC
Via Business Wire
ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Intra-Cellular Therapies Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews
Via Benzinga
Nike To Rally Over 50%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
This Conagra Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Via Benzinga
Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst
Via Benzinga
Exposures Product Safety
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LGTY, ENFN, ITCI, SSTK on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Logility Supply Chain Solutions, Inc. (Nasdaq - LGTY), Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Shutterstock, Inc. (NYSE - SSTK)
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Logility Supply Chain Solutions, Inc. (Nasdaq - LGTY), Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Shutterstock, Inc. (NYSE - SSTK)
From Brodsky & Smith LLC
Via GlobeNewswire
Johnson & Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outlook
Via Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN, ITCI, HEES, SSTK on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), H&E Equipment Services, Inc. (Nasdaq - HEES), Shutterstock, Inc. (NYSE - SSTK)
From Brodsky & Smith LLC
Via GlobeNewswire
Top 4 Health Care Stocks You May Want To Dump In Q1
Via Benzinga
MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Via Benzinga
MarketBeat Week in Review – 01/13 - 01/17
Via MarketBeat
Topics Economy Energy
Exposures Fossil Fuels Interest Rates
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Is Johnson & Johnson Stock Set to Reward Long-Term Holders?
Via MarketBeat
Exposures Product Safety
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN, ITCI, EDBL on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI
From Kahn Swick & Foti, LLC
Via Business Wire
Shareholder Alert: Ademi LLP investigates whether Intra-Cellular Therapies, Inc. is obtaining a Fair Price for its Public Shareholders
From Ademi LLP
Via Business Wire
Intra-Cellular Therapies Stock Is Surging Monday: What's Going On?
Via Benzinga
Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge
Via Benzinga

Frequently Asked Questions

Is Intra-Cellular Therapies Inc. - Common Stock publicly traded?
Yes, Intra-Cellular Therapies Inc. - Common Stock is publicly traded.
What exchange does Intra-Cellular Therapies Inc. - Common Stock trade on?
Intra-Cellular Therapies Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Intra-Cellular Therapies Inc. - Common Stock?
The ticker symbol for Intra-Cellular Therapies Inc. - Common Stock is ITCI on the Nasdaq Stock Market
What is the current price of Intra-Cellular Therapies Inc. - Common Stock?
The current price of Intra-Cellular Therapies Inc. - Common Stock is 131.88
When was Intra-Cellular Therapies Inc. - Common Stock last traded?
The last trade of Intra-Cellular Therapies Inc. - Common Stock was at 03/31/25 01:24 PM ET
What is the market capitalization of Intra-Cellular Therapies Inc. - Common Stock?
The market capitalization of Intra-Cellular Therapies Inc. - Common Stock is 12.44B
How many shares of Intra-Cellular Therapies Inc. - Common Stock are outstanding?
Intra-Cellular Therapies Inc. - Common Stock has 12B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.